8-KAnnualMeetingMay2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 5, 2014
    
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)

Delaware
000-27756
13-3648318
------------------
------------------
---------------
(State or other jurisdiction of
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)


352 Knotter Drive, Cheshire, Connecticut 06410
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code:    (203) 272-2596
   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))






Item 5.07    Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc. held its Annual Meeting of Shareholders on May 5, 2014 in New Haven, Connecticut. The results of the matters voted on by the shareholders are set forth below.

1.    The election of directors:
 

Votes For
 
Votes Against or Withheld
 

Abstentions
 
Broker
Non-Votes
 
 
 
 
 
 
 
 
Max Link
168,235,753
 
210,549
 
2,862,836
 
7,797,214
Leonard Bell
169,311,315
 
27,037
 
1,970,786
 
7,797,214
William R. Keller
167,960,262
 
1,627,939
 
1,720,937
 
7,797,214
John T. Mollen
170,991,273
 
25,706
 
292,159
 
7,797,214
R. Douglas Norby
166,950,241
 
1,883,117
 
2,475,780
 
7,797,214
Alvin S. Parven
160,539,189
 
5,081,881
 
5,688,068
 
7,797,214
Andreas Rummelt
169,588,445
 
34,450
 
1,686,243
 
7,797,214
Ann M. Veneman
168,014,717
 
1,608,086
 
1,686,335
 
7,797,214

2.
The non-binding advisory vote to approve the compensation paid to Alexion’s named executive officers as described in Alexion’s 2014 proxy statement:

Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
 
 
 
 
 
 
 
169,768,073
 
1,306,664
 
234,401
 
7,797,214

3.
Ratification of the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
178,363,991
 
586,348
 
156,013

4.
Shareholder proposal requesting the Board of Directors to adopt a rule to redeem any current or future shareholder rights plan, or amendment thereto, unless such plan is submitted to a shareholder vote within 12 months:

Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
 
 
 
 
 
 
 
156,364,027
 
13,846,822
 
1,098,289
 
7,797,214





Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 7, 2014
 
ALEXION PHARMACEUTICALS, INC.
 
 
By:    /s/ Michael V. Greco      
Name: Michael V. Greco
Title: Vice President of Law and Corporate Secretary